Literature DB >> 27401123

On the Origin of CRISPR-Cas Technology: From Prokaryotes to Mammals.

Francisco J M Mojica1, Lluis Montoliu2.   

Abstract

Clustered regularly-interspaced short palindromic repeat (CRISPR) sequences cooperate with CRISPR-associated (Cas) proteins to form the basis of CRISPR-Cas adaptive immune systems in prokaryotes. For more than 20 years, these systems were of interest only to specialists, mainly molecular microbiologists, who tried to understand the properties of this unique defense mechanism. In 2012, the potential of CRISPR-Cas systems was uncovered and these were presented as genome-editing tools with an outstanding capacity to trigger targeted genetic modifications that can be applied to virtually any organism. Shortly thereafter, in early 2013, these tools were shown to efficiently drive specific modification of mammalian genomes. This review attempts to summarize, in a comprehensive manner, the key events and milestones that brought CRISPR-Cas technology from prokaryotes to mammals.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  gene disruption; gene replacement; gene therapy; genetic modification; genome-editing nucleases; homologous recombination

Mesh:

Year:  2016        PMID: 27401123     DOI: 10.1016/j.tim.2016.06.005

Source DB:  PubMed          Journal:  Trends Microbiol        ISSN: 0966-842X            Impact factor:   17.079


  41 in total

Review 1.  Usefulness of knockout mice to clarify the role of the opioid system in chronic pain.

Authors:  Rafael Maldonado; Josep Eladi Baños; David Cabañero
Journal:  Br J Pharmacol       Date:  2018-01-06       Impact factor: 8.739

Review 2.  Target-specific gene delivery in plant systems and their expression: Insights into recent developments.

Authors:  Debdyuti Nandy; Amrita Maity; Arup Kumar Mitra
Journal:  J Biosci       Date:  2020       Impact factor: 1.826

Review 3.  CRISPR/Cas9 facilitates genomic editing for large-scale functional studies in pluripotent stem cell cultures.

Authors:  Xiao-Fei Li; Yong-Wei Zhou; Peng-Fei Cai; Wei-Cong Fu; Jin-Hua Wang; Jin-Yang Chen; Qi-Ning Yang
Journal:  Hum Genet       Date:  2019-10-12       Impact factor: 4.132

4.  Genome Editing: Promoting Responsible Research.

Authors:  François Hirsch; Christine Lemaitre; Hervé Chneiweiss; Lluis Montoliu
Journal:  Pharmaceut Med       Date:  2019-06

Review 5.  A history of genome editing in mammals.

Authors:  Almudena Fernández; Santiago Josa; Lluis Montoliu
Journal:  Mamm Genome       Date:  2017-06-06       Impact factor: 2.957

6.  Xenotransplantation: Progress Along Paths Uncertain from Models to Application.

Authors:  Jeffrey L Platt; Marilia Cascalho; Jorge A Piedrahita
Journal:  ILAR J       Date:  2018-12-31

7.  Establishment of a conditional Nomo1 mouse model by CRISPR/Cas9 technology.

Authors:  Ignacio García-Tuñón; Elena Vuelta; Laura Lozano; María Herrero; Lucía Méndez; Javier Palomero-Hernandez; María Pérez-Caro; Jessica Pérez-García; Rogelio González-Sarmiento; Manuel Sánchez-Martín
Journal:  Mol Biol Rep       Date:  2019-12-12       Impact factor: 2.316

8.  Diversification of the CRISPR Toolbox: Applications of CRISPR-Cas Systems Beyond Genome Editing.

Authors:  Sarah Balderston; Gabrielle Clouse; Juan-José Ripoll; Grace K Pratt; Giedrius Gasiunas; Jens-Ole Bock; Eric Paul Bennett; Kiana Aran
Journal:  CRISPR J       Date:  2021-06

9.  Application of CRISPR-Cas9 gene editing for congenital heart disease.

Authors:  Heeyoung Seok; Rui Deng; Douglas B Cowan; Da-Zhi Wang
Journal:  Clin Exp Pediatr       Date:  2021-03-02

Review 10.  Genome engineering and disease modeling via programmable nucleases for insulin gene therapy; promises of CRISPR/Cas9 technology.

Authors:  Yunus E Eksi; Ahter D Sanlioglu; Bahar Akkaya; Bilge Esin Ozturk; Salih Sanlioglu
Journal:  World J Stem Cells       Date:  2021-06-26       Impact factor: 5.326

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.